Inhibrx Inc
NASDAQ:INBX
Inhibrx Inc
Net Issuance of Common Stock
Inhibrx Inc
Net Issuance of Common Stock Peer Comparison
Competitive Net Issuance of Common Stock Analysis
Latest Figures & CAGR of Competitors
Company | Net Issuance of Common Stock | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Inhibrx Inc
NASDAQ:INBX
|
Net Issuance of Common Stock
$202.3m
|
CAGR 3-Years
14%
|
CAGR 5-Years
58%
|
CAGR 10-Years
N/A
|
|
Abbvie Inc
NYSE:ABBV
|
Net Issuance of Common Stock
-$1.1B
|
CAGR 3-Years
-9%
|
CAGR 5-Years
37%
|
CAGR 10-Years
-18%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Net Issuance of Common Stock
-$719m
|
CAGR 3-Years
-22%
|
CAGR 5-Years
22%
|
CAGR 10-Years
-2%
|
|
Amgen Inc
NASDAQ:AMGN
|
Net Issuance of Common Stock
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Net Issuance of Common Stock
-$288.7m
|
CAGR 3-Years
15%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
N/A
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Net Issuance of Common Stock
-$473.2m
|
CAGR 3-Years
51%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Inhibrx Inc's Net Issuance of Common Stock?
Net Issuance of Common Stock
202.3m
USD
Based on the financial report for Dec 31, 2023, Inhibrx Inc's Net Issuance of Common Stock amounts to 202.3m USD.
What is Inhibrx Inc's Net Issuance of Common Stock growth rate?
Net Issuance of Common Stock CAGR 5Y
58%
Over the last year, the Net Issuance of Common Stock growth was 55%. The average annual Net Issuance of Common Stock growth rates for Inhibrx Inc have been 14% over the past three years , 58% over the past five years .